Karyopharm Therapeutics (KPTI) Competitors $3.95 -0.02 (-0.50%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. GNLX, CGEN, KRRO, SPRO, BHST, FATE, MCRB, IMRX, PLX, and IKTShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Genelux (GNLX), Compugen (CGEN), Korro Bio (KRRO), Spero Therapeutics (SPRO), BioHarvest Sciences (BHST), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Immuneering (IMRX), Protalix BioTherapeutics (PLX), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Genelux Compugen Korro Bio Spero Therapeutics BioHarvest Sciences Fate Therapeutics Seres Therapeutics Immuneering Protalix BioTherapeutics Inhibikase Therapeutics Karyopharm Therapeutics (NASDAQ:KPTI) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment. Does the media prefer KPTI or GNLX? In the previous week, Genelux had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Genelux and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Genelux'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in KPTI or GNLX? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 3.0% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate KPTI or GNLX? Karyopharm Therapeutics currently has a consensus target price of $37.40, indicating a potential upside of 846.84%. Genelux has a consensus target price of $17.75, indicating a potential upside of 421.29%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts plainly believe Karyopharm Therapeutics is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk and volatility, KPTI or GNLX? Karyopharm Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Genelux has a beta of -0.32, suggesting that its share price is 132% less volatile than the S&P 500. Which has stronger earnings and valuation, KPTI or GNLX? Genelux has lower revenue, but higher earnings than Karyopharm Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.23-$76.42M-$13.26-0.30GeneluxN/AN/A-$29.87M-$0.88-3.87 Is KPTI or GNLX more profitable? Genelux has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%. Karyopharm Therapeutics' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-43.99% N/A -35.95% Genelux N/A -93.04%-74.17% SummaryKaryopharm Therapeutics and Genelux tied by winning 7 of the 14 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.09M$2.42B$5.46B$9.64BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-0.3019.7130.0125.17Price / Sales0.23426.05372.2177.01Price / CashN/A165.0335.9458.58Price / Book-0.184.158.155.69Net Income-$76.42M$31.61M$3.26B$265.48M7 Day Performance0.51%0.76%1.05%2.60%1 Month Performance-15.05%2.86%2.75%1.95%1 Year Performance-68.59%4.14%28.06%23.97% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.4534 of 5 stars$3.95-0.5%$37.40+846.8%-67.4%$34.09M$145.24M-0.30380Upcoming EarningsGNLXGenelux1.1478 of 5 stars$3.51flat$17.75+405.7%+73.1%$132.54M$10K-3.9910News CoverageEarnings ReportUpcoming EarningsGap UpCGENCompugen1.6637 of 5 stars$1.46-1.4%$4.00+174.0%-11.7%$132.07M$27.86M-9.1370News CoverageEarnings ReportKRROKorro Bio1.4388 of 5 stars$15.49+11.8%$102.43+561.3%-55.4%$130.06M$2.27M-1.6470Upcoming EarningsGap UpSPROSpero Therapeutics3.8536 of 5 stars$2.26-1.7%$5.00+121.2%+76.4%$128.59M$47.98M-1.77150BHSTBioHarvest SciencesN/A$7.67-0.3%$13.67+78.2%N/A$126.28M$27.70M-15.34N/ANews CoverageUpcoming EarningsFATEFate Therapeutics3.9859 of 5 stars$1.06-0.9%$3.83+261.6%-75.4%$122.63M$13.63M-0.71550Upcoming EarningsMCRBSeres Therapeutics3.1472 of 5 stars$14.78+5.6%$73.67+398.4%-13.1%$122.17M$126.32M-3.21330Earnings ReportIMRXImmuneering3.4438 of 5 stars$3.43+1.8%$13.25+286.3%+207.9%$121.27MN/A-1.7560Positive NewsPLXProtalix BioTherapeutics2.4116 of 5 stars$1.50+3.4%$15.00+900.0%+51.0%$119.41M$59.76M-11.54200IKTInhibikase Therapeutics1.6662 of 5 stars$1.60+5.3%$6.50+306.3%+22.0%$118.95MN/A-0.606 Related Companies and Tools Related Companies Genelux Competitors Compugen Competitors Korro Bio Competitors Spero Therapeutics Competitors BioHarvest Sciences Competitors Fate Therapeutics Competitors Seres Therapeutics Competitors Immuneering Competitors Protalix BioTherapeutics Competitors Inhibikase Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts